sunitinib zentiva 12,5 mg hartkapseln
zentiva pharma gmbh (8075753) - sunitinib - hartkapsel - 12,5 mg - sunitinib (31615) 12,5 milligramm
sunitinib zentiva 25 mg hartkapseln
zentiva pharma gmbh (8075753) - sunitinib - hartkapsel - 25 mg - sunitinib (31615) 25 milligramm
sunitinib zentiva 37,5 mg hartkapseln
zentiva pharma gmbh (8075753) - sunitinib - hartkapsel - 37,5 mg - sunitinib (31615) 37,5 milligramm
sunitinib zentiva 50 mg hartkapseln
zentiva pharma gmbh (8075753) - sunitinib - hartkapsel - 50 mg - sunitinib (31615) 50 milligramm
sunitinib denk 12,5 mg hartkapseln
denk pharma gmbh & co. kg (8128863) - sunitinib - hartkapsel - 12,5 mg - sunitinib (31615) 12,5 milligramm
sunitinib denk 25 mg hartkapseln
denk pharma gmbh & co. kg (8128863) - sunitinib - hartkapsel - 25 mg - sunitinib (31615) 25 milligramm
sunitinib denk 50 mg hartkapseln
denk pharma gmbh & co. kg (8128863) - sunitinib - hartkapsel - 50 mg - sunitinib (31615) 50 milligramm
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastische mittel - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
sunitinib-ratiopharm 37,5 mg hartkapseln
ratiopharm gmbh (3087881) - sunitinib - hartkapsel - sunitinib (31615) 37,5 milligramm
sunitinib-ratiopharm 50 mg hartkapseln
ratiopharm gmbh (3087881) - sunitinib - hartkapsel - sunitinib (31615) 50 milligramm